Indian CDMOs pivot to biologics and peptides for next growth phase

India's contract development and manufacturing organization (CDMO) sector is undergoing a significant transformation as players seek to establish capabilities in high-value, complex pharmaceutical products. The shift toward biologics, peptides, and drug-device combinations marks a departure from the industry's traditional focus on generic and small-molecule drug manufacturing, according to statements from industry executives.

The move reflects broader changes in global pharmaceutical development patterns, where drug sponsors increasingly outsource manufacturing of specialized therapeutics to specialized partners. Biologics and peptide-based medicines command premium pricing and represent faster-growing segments within the pharmaceutical market compared to conventional drugs, making them attractive targets for CDMOs seeking higher-margin contracts.

CDMO operators cite significant infrastructure investments required to establish biologics and peptide manufacturing capabilities, including specialized facilities, equipment, and technical expertise. Companies developing these advanced manufacturing competencies position themselves to capture a larger share of global outsourcing opportunities as multinational pharmaceutical firms continue expanding their use of contract manufacturers for complex drug categories.

Industry observers note that successful execution of this strategy depends on CDMOs' ability to attract qualified personnel, secure regulatory approvals, and demonstrate consistent quality standards. The transition also requires substantial capital expenditure and long-term commitment to research and development to build proprietary processes and differentiate offerings in an increasingly competitive market.